 		   Mallinckrodt has begun selling its Optistar MR contrast power injectors in the U.S. following FDA clearance of the device in December. Optistar is also being sold in Canada. St. Louis-based Mallinckrodt, which is working to become a single-source supplier for the contrast imaging market, estimates the annual market for power injectors to be around $35 million.

In related news, Mallinckrodt management is expanding its share repurchase program during the balance of this fiscal year (end-June) due to recent weakness in the companys stock price. So far this fiscal year, the company has repurchased 2.8 million shares of its stock at a market value of $90 million.			

Mallinckrodt has begun selling its Optistar MR contrast power injectors in the U.S. following FDA clearance of the device in December. Optistar is also being sold in Canada. St. Louis-based Mallinckrodt, which is working to become a single-source

Mallinckrodt debuts MR contrast injectors